Last reviewed · How we verify

NCT01583881: DIASTOLE

Denervation of the renAl sympathetIc nerveS in hearT Failure With nOrmal Lv Ejection Fraction

Terminated Phase 2, PHASE3 Last updated 3 May 2021
What this trial tests

Phase 2, PHASE3 trial testing renal denervation in Diastolic Heart Failure in 60 participants. Terminated before completion.

Timeline
1 April 2012
Primary endpoint
1 June 2016
1 July 2016

Quick facts

Lead sponsorUMC Utrecht
PhasePhase 2, PHASE3
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment60
Start date1 April 2012
Primary completion1 June 2016
Estimated completion1 July 2016
Sites2 locations across Netherlands

Drugs / interventions tested

Conditions studied

Sponsor

UMC Utrecht — full company profile →

Who can join

18 and older, any sex, with Diastolic Heart Failure or Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Increasing evidence suggests an important role of activation of the sympathetic nervous system (SNS) in the clinical phenomena of heart failure with normal left ventricular ejection fraction and hypertension. The current study aims to evaluate efficacy and safety of renal sympathetic denervation for the modulation of the SNS in patients with heart failure with normal LV ejection fraction.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Renal denervation in heart failure with normal left ventricular ejection fraction. Rationale and design of the DIASTOLE (DenervatIon of the renAl Sympathetic nerves in hearT failure with nOrmal Lv Ejection fraction) trial.
    Verloop WL, Beeftink MM, Nap A, Bots ML, et al · · 2013 · cited 34× · PMID 23883653 · DOI 10.1093/eurjhf/hft119
  2. Autonomic nervous system and cardiac neuro-signaling pathway modulation in cardiovascular disorders and Alzheimer's disease.
    Elia A, Fossati S. · · 2023 · cited 29× · PMID 36798942 · DOI 10.3389/fphys.2023.1060666
  3. Renal denervation for resistant hypertension.
    Coppolino G, Pisano A, Rivoli L, Bolignano D. · · 2017 · cited 22× · PMID 28220472 · DOI 10.1002/14651858.cd011499.pub2
  4. Renal denervation for resistant hypertension.
    Pisano A, Iannone LF, Leo A, Russo E, et al · · 2021 · cited 14× · PMID 34806762 · DOI 10.1002/14651858.cd011499.pub3
  5. Renal denervation beyond the bifurcation: The effect of distal ablation placement on safety and blood pressure.
    Beeftink MM, Spiering W, De Jong MR, Doevendans PA, et al · · 2017 · cited 8× · PMID 28296025 · DOI 10.1111/jch.12989
  6. Neuromodulation Therapies in Heart Failure: A State-of-the-Art Review.
    Pahuja M, Akhtar KH, Krishan S, Nasir YM, et al · · 2023 · cited 5× · PMID 39131073 · DOI 10.1016/j.jscai.2023.101199
  7. Device-Based Sympathetic Nerve Regulation for Cardiovascular Diseases.
    Li L, Hu Z, Xiong Y, Yao Y. · · 2021 · cited 4× · PMID 34957267 · DOI 10.3389/fcvm.2021.803984
  8. Reconsidering Renal Sympathetic Denervation for Heart Failure.
    Tang WHW, Dunlap ME. · · 2017 · cited 2× · PMID 30062149 · DOI 10.1016/j.jacbts.2017.05.003

Verify or expand the search:

Other trials of renal denervation

Trials testing the same drug.

Other recruiting trials for Diastolic Heart Failure

Currently open trials in the same condition.

Other UMC Utrecht trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01583881.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing